Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3739 - Relationship between androgen receptor and tumor infiltrating lymphocytes in triple negative breast cancer

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Luis Felipe Sánchez-Cousido

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

L.F. Sánchez-Cousido1, A. López-González1, E. Honrado Franco2, E. Vallejo Pascual3, O. Sanz4, L. Lopez Gonzalez5, I. Delgado1, M. López-Flores6, A. García Palomo6

Author affiliations

  • 1 Oncology, Complejo Asistencial Universitario de León, 24071 - Leon/ES
  • 2 Pathology, Complejo Asistencial Universitario de León, León/ES
  • 3 Economic And Statistic, Universidad de León, León/ES
  • 4 General Surgery, Complejo Asistencial Universitario de León, León/ES
  • 5 Radiology, Complejo Asistencial Universitario de León, León/ES
  • 6 Oncología Médica, Complejo Asistencial Universitario de León, León/ES
More

Resources

Abstract 3739

Background

Triple-negative breast cancer (TNBC) is considered a poor prognostic subtype and a heterogeneous entity. Its only treatment is chemotherapy. Immunotherapy and antiandrogen therapies are being tested. Androgen receptor (AR) is expressed in up to 53% of TNBC. It is associated with a better disease-free survival and overall survival. The relation between tumor infiltrating lymphocytes (TIL) and AR in urothelial cancers has been assessed, unlike in TNBC.

Methods

50 stage I-III TNBC patients diagnosed between 2008 and 2013 were analyzed. Minimum follow-up was 57 months or until death. On these samples fixed in 10% formalin and included in paraffin, the evaluation of the expression of AR, CD20, CD4 and CD8 was performed by immunohistochemistry. AR+ was defined by more than 1% expression. Lymphocytes were evaluated as per the recommendations of the International Expert Consensus. We also analyzed total lymphocytes as high/low if they were over/under 80%. Data was analyzed by SPSS version 23.

Results

Clinical characteristics are as follows: mean age of 61 years old, and postmenopausal 68%. 74% of the patients did not relapse and progression-free survival (PFS) was 95,6 months. Main tumor characteristics were Ki67>20%, 67,3%; T1-T2 88%; high grade 67,4%; lymph node (N) positive 51%. Early stage (stage I-II) was the 80%. High level of lymphocytes (HiL) was present in 70% of them. AR + (26%) was associated with younger patients (p = 0.009), low Ki67 (p = 0.014) and N + (p=0.025). No relation was obtained between AR and TIL, tumor size, grade, stage or survival. CD8+ were more present in AR + (p=0.002) and so the proportion CD4/CD8 (CD8>CD4 in AR+; CD4>CD8 in AR-. p = 0.026) HiL was related with higher Ki67 (p = 0.021) and grade 3 (p = 0.029). However, lower relapse and also lower deaths were observed in those with HiL (15.4% vs 84.6%; 21.4% vs 78.6%). In HiL, percentage of CD8+ was inversely proportional (p = 0.021 mean 27,7%).

Conclusions

High grade tumors and higher Ki67 unleash a higher immune response, protecting from a worse prognosis. CD8+ lymphocytes are associated with AR expression. More studies are needed to understand the relationship between AR and TIL and also the role of AR blockade in TNBC and its role in immune-mediated lysis.

Clinical trial identification

Legal entity responsible for the study

Complejo Asistencial Universitario de León.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.